The mR­NA uni­corn Mod­er­na has more ear­ly-stage hu­man da­ta it wants to show off — reach­ing new peaks in prov­ing the po­ten­tial

The whole mes­sen­ger RNA field has at­tract­ed bil­lions of dol­lars in pub­lic and pri­vate in­vestor cash gam­bled on the prospect of get­ting in on the ground floor. And this morn­ing Boston-based Mod­er­na, one of the lead­ers in the field, wants to show off a few more of the cards it has to play to prove to you that they’re re­al­ly in the game.

The whole hand, of course, has yet to be dealt. And there’s no telling who gets to walk with a share of the pot. But any cards on dis­play at this point — es­pe­cial­ly af­ter be­ing ac­cused of keep­ing its deck un­der lock and key — will at­tract plen­ty of at­ten­tion from some very wary, and wired, ob­servers.

“In terms of the com­plex­i­ty and un­met need,” says Tal Zaks, the chief med­ical of­fi­cer, “this is peak for what we’ve ac­com­plished.”

Mod­er­na has two Phase I stud­ies it wants to talk about now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER